(Press-News.org) Researchers from UCLA's Jonsson Comprehensive Cancer Center, together with scientists from 12 other sites in the United States and Australia, report for the first time that a newly approved drug for patients with metastatic melanoma nearly doubles median survival times, a finding that will change the way this deadly form of skin cancer is treated.
The data comes from an international Phase II study of Zelboraf that included 132 patients followed for at least one year.
Patients with this advanced form of melanoma that has spread to other organs typically survive about nine months. Patients taking Zelboraf, which blocks a mutated BRAF protein, survived an average of 15.9 months, said study senior author Dr. Antoni Ribas, a professor of hematology/oncology and a researcher at UCLA's Jonsson Cancer Center.
"This study shows that Zelboraf changes the natural history of this disease," Ribas said. "This data is beyond what I would have expected. We're seeing a significant number of patients with durable responses to the drug, and that the whole group of treated patients is living longer. These results tell us that this drug is having a very big impact, and this changes the way we treat metastatic melanoma."
The study appears Feb. 23, 2012 in the peer-reviewed New England Journal of Medicine.
About 50 percent of patients with metastatic melanoma, or 4,000 people a year, have the BRAF mutation and can be treated with Zelboraf, a pill taken twice a day, Ribas said. Of those, 53 percent have an objective response to the drug, meaning their tumors shrink by more than 30 percent. An additional 30 percent of patients have tumor responses of lesser magnitude. Only 14 percent of patients with the BRAF mutation failed to respond to Zelboraf.
The drug represents a breakthrough in treating metastatic melanoma. Prior to this, 10 percent or less of patients with this advanced form of the disease responded to any of the available conventional treatments, Ribas said.
"We knew this drug would make the melanomas shrink in a large proportion of patients and that it worked better than chemotherapy," Ribas said. "We did not know that patients taking Zelboraf were living longer until now."
The main limitation with Zelboraf is that tumors eventually become resistant. But Jonsson Cancer Center researchers are studying this resistance and have uncovered several mechanisms by which the cancer gets around Zelboraf. Cancer center scientists currently are seeking agents to target those mechanisms, Ribas said.
For Louise Belley, 60, of Santa Ana, Zelboraf has allowed her to live much longer than her doctors initially predicted, and last June she was able to see her daughter graduate from college. Belley was diagnosed with metastatic melanoma in November of 2007. In June 2009, she was among the first people to get the drug when it was in Phase I studies at the Jonsson Cancer Center.
Her first CT scan in September 2009 after joining the trial - nearly two and a half years ago - was clear of any cancer, she said. Her scans remain clean today.
"At first I was devastated by my diagnosis, because I realized I was in a really bad place," Belley said. "But now I feel strongly that the chances are good that I will continue to be cancer free, and I plan to live every day to the fullest."
Zelboraf was approved by the U.S. Food and Drug Administration for use in metastatic melanoma in August of 2011. About 70,000 new cases of melanoma are diagnosed each year in the United States. Of those, 8,000 people will die of the disease.
"This trial shows a high rate of response to (Zelboraf) in patients with metastatic melanoma and activating BRAF mutations," the study states. "These results independently confirm the high response rate and response duration shown in a Phase I trial."
###
UCLA's Jonsson Comprehensive Cancer Center has more than 240 researchers and clinicians engaged in disease research, prevention, detection, control, treatment and education. One of the nation's largest comprehensive cancer centers, the Jonsson center is dedicated to promoting research and translating basic science into leading-edge clinical studies. In July 2011, the Jonsson Cancer Center was named among the top 10 cancer centers nationwide by U.S. News & World Report, a ranking it has held for 11 of the last 12 years. For more information on the Jonsson Cancer Center, visit our website at http://www.cancer.ucla.edu.
END
The Virginia Tech – Wake Forest University School of Biomedical Engineering and Sciences (SBES) announces the first ever publication with data on head impacts from youth football players. The paper is published in the Annals of Biomedical Engineering and is available online for free download. The manuscript includes the details of over 700 head impacts measured on 7 and 8 year old youth football players.
Based on the importance of this initial publication, the School of Biomedical Engineering and Sciences is also announcing today a new study to instrument and map the ...
Nursing homes are supposed to provide quality care, but recent studies raise concerns that some of these homes put our elderly population at increased risk of injury and death. The studies, conducted by both the Government Accountability Office and Health Services Research, found well-known nursing home chains often violate federal regulations in ways that can lead to increased risk of nursing home injuries.
Connection Between For-Profit Facilities and Poor Care
The Government Accountability Office published a study in July of 2011, reviewing complaints that for-profit ...
CAMBRIDGE, Mass. (February 22, 2012) – If you were to discover that a fundamental component of human biology has survived virtually intact for the past 25 million years, you'd be quite confident in saying that it is here to stay.
Such is the case for a team of Whitehead Institute scientists, whose latest research on the evolution of the human Y chromosome confirms that the Y—despite arguments to the contrary—has a long, healthy future ahead of it.
Proponents of the so-called rotting Y theory have been predicting the eventual extinction of the Y chromosome since it was ...
Bird migration timing across North America has been affected by climate change, according to a study published Feb. 22 in the open access journal PLoS ONE. The results are based on a systematic analysis of observations from amateur birdwatchers. This citizen science approach provided access to data for 18 common North American bird species, including orioles, house wrens, and barn swallows, across an unprecedented geographical region.
The researchers, led by Allen Hurlbert of University of North Carolina, Chapel Hill, found that the average arrival time for all species ...
Workers face many dangers on construction sites, including falls from heights and unsafe scaffolds or ladders. At any busy worksite, construction workers are also at risk of being struck by falling objects.
A recent New York Court of Appeals opinion, Wilinski v. 334 East 92nd Housing Development Fund, considered a worker's remedies for a Manhattan construction accident that occurred during demolition of a brick wall in a vacant warehouse. The worker suffered serious and lasting injuries when he was struck on the head, shoulder and arm by two ten-foot long, four-inch ...
Stress is known to lead to short-term escape behavior, and new research on elephants in South Africa shows that it can also cause long-term escape behavior, affecting the extent that elephants use their habitat. The work is published Feb. 22 in the open access journal PLoS ONE.
The researchers, led by David Jachowski of the University of Missouri, measured levels of FGM (fecal glucocorticoid metabolite), a proxy of physiological stress, and land use patterns for three different elephant populations, and found that higher FGM was associated with 20-43% lower land usage. ...
Like drivers in every other state, South Carolina motorists face their share of hazards that lead to car, truck and motorcycle accidents. From drunk drivers to dangerous roadways and defective tires or brakes, there are often several reasons why an accident occurred and people suffered injuries.
One common factor from coast to coast: inexperienced drivers pose more than their share of risks to themselves and other motorists and passengers as they learn to drive in various types of weather and traffic. A recent study published by the AAA Foundation for Traffic Safety ...
Nanoparticles have many useful applications, but also raise some potential health and ecological concerns. Now, new research shows that plastic nanoparticles are transported through the aquatic food chain and affect fish metabolism and behavior. The full report is published Feb. 22 in the open access journal PLoS ONE.
Exposing fish to nanoparticles slowed their feeding behavior, and also affected metabolic parameters including weight loss and cholesterol levels and distribution. The authors, led by Tommy Cedervall, Lars-Anders Hansson and Sara Linse of Lund University ...
Researchers have discovered an extremely old anthropomorphic figure engraved in rock in Brazil, according to a report published Feb. 22 in the open access journal PLoS ONE. The petroglyph, which dates to between 9,000 and 12,000 years old, is the oldest reliably dated instance of such rock art yet found in the Americas.
Art from this time period in the New World is quite rare, so little is known about the diversity of symbolic thinking of the early American settlers. The authors of this study, led by Walter Neves of the University of Sao Paulo, write that their findings ...
A fundamental discovery reported in the March 1st issue of the journal Nature, uncovers the first molecular evidence linking the body's natural circadian rhythms to sudden cardiac death (SCD). Ventricular arrhythmias, or abnormal heart rhythms, are the most common cause of sudden cardiac death: the primary cause of death from heart disease. They occur most frequently in the morning waking hours, followed by a smaller peak in the evening hours. While scientists have observed this tendency for many years, prior to this breakthrough, the molecular basis for these daily patterns ...
